sv3
As filed with the Securities and Exchange Commission on
May 18, 2006
Registration
No. 333-
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SOLEXA, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
94-3161073 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
|
|
25861 Industrial Boulevard
Hayward, California 94545
(510) 670-9300
(Address, including zip code, and telephone number,
including area code, of registrants principal executive
offices) |
|
John West
Chief Executive Officer
Solexa, Inc.
25861 Industrial Boulevard
Hayward, California 94545
(510) 670-9300
(Name, address, including zip code, and telephone
number,
including area code, of agent for service) |
Copy to:
James C. Kitch, Esq.
Cooley Godward LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
(650) 843-5000
Approximate date of proposed sale to the public:
From time to time after the effective date of this
Registration Statement.
If the only securities being registered on this form are being
offered pursuant to dividend or interest reinvestment plans,
please check the following
box. o
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or interest
reinvestment plans, check the following
box. þ
If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act
registration statement number of the earlier effective
registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering. o
If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that
shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the
following box. o
If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to
register additional classes of securities pursuant to
Rule 413(b) under the Securities Act, check the following
box. o
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed Maximum |
|
|
Amount of |
Title of Securities to be Registered |
|
|
Aggregate Offering Price(1) |
|
|
Registration Fee |
|
|
|
|
|
|
|
Common Stock, $0.01 par value per share
|
|
|
(2) |
|
|
|
|
|
|
|
|
|
|
Preferred Stock, $0.01 par value per share
|
|
|
(2) |
|
|
|
|
|
|
|
|
|
|
Warrants
|
|
|
(2) |
|
|
|
|
|
|
|
|
|
|
Debt Securities
|
|
|
(2) |
|
|
|
|
|
|
|
|
|
|
Units
|
|
|
(2) |
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
$100,000,000 |
|
|
$10,700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
There are being registered hereunder such indeterminate number
of shares of common stock and preferred stock, such
indeterminate principal amount of debt securities, such
indeterminate number of warrants to purchase common stock,
preferred stock or debt securities, and such indeterminate
number of units as shall have an aggregate initial offering
price not to exceed $100,000,000. If any debt securities are
issued at an original issue discount, then the offering price of
such debt securities shall be in such greater principal amount
as shall result in an aggregate initial offering price not to
exceed $100,000,000, less the aggregate dollar amount of all
securities previously issued hereunder. Any securities
registered hereunder may be sold separately or as units with
other securities registered hereunder. The proposed maximum
initial offering price per unit will be determined, from time to
time, by the registrant in connection with the issuance by the
registrant of the securities registered hereunder. The
securities registered also include such indeterminate number of
shares of common stock and preferred stock and amount of debt
securities as may be issued upon conversion of or exchange for
preferred stock or debt securities that provide for conversion
or exchange, upon exercise of warrants or pursuant to the
antidilution provisions of any such securities. In addition,
pursuant to Rule 416 under the Securities Act, the shares
being registered hereunder include such indeterminate number of
shares of common stock and preferred stock as may be issuable
with respect to the shares being registered hereunder as a
result of stock splits, stock dividends or similar transactions. |
|
(2) |
The proposed maximum aggregate offering price per class of
security will be determined from time to time by the registrant
in connection with the issuance by the registrant of the
securities registered hereunder and is not specified as to each
class of security pursuant to General Instruction II.D. of
Form S-3 under the
Securities Act. |
The Registrant hereby amends this Registration Statement on
such date or dates as may be necessary to delay its effective
date until the registrant shall file a further amendment that
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to said
Section 8(a), may determine.
The information
in this prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed
with the Securities and Exchange Commission is effective. This
prospectus is not an offer to sell these securities and is not
soliciting an offer to buy these securities in any state where
the offer or sale is not
permitted.
|
SUBJECT TO COMPLETION, DATED
MAY 18, 2006
PROSPECTUS
$100,000,000 Shares
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
From time to time, we may sell common stock, preferred stock,
debt securities and/or warrants, either individually or in
units, with a total value of up to $100 million. We may
also offer common stock or preferred stock upon conversion of
debt securities, common stock upon conversion of preferred
stock, or common stock, preferred stock or debt securities upon
the exercise of warrants.
We will provide specific terms of these offerings and securities
in one or more supplements to this prospectus. The prospectus
supplement may also add, update or change information contained
in this prospectus. You should read this prospectus and any
prospectus supplement, as well as any documents incorporated by
reference in this prospectus and any prospectus supplement,
carefully before you invest.
Our common stock is traded on the NASDAQ Global Market under the
symbol SLXA. On May 17, 2006, the last reported
sale price of our common stock was $9.33 per share. The
applicable prospectus supplement will contain information, where
applicable, as to any other listing, if any, on the NASDAQ
Global Market or any securities market or other exchange of the
securities covered by the prospectus supplement.
Investing in our securities involves a high degree of risk.
See the section entitled Risk Factors contained
herein at page 2, in any supplements to this prospectus and
in our most recent annual report on
Form 10-K and in
our most recent quarterly report on
Form 10-Q, as well
as any amendments thereto, as filed with the Securities and
Exchange Commission, and which are incorporated herein by
reference in their entirety.
This prospectus may not be used to offer or sell any
securities unless accompanied by a prospectus supplement.
The securities may be sold directly by us to investors, through
agents designated from time to time or to or through
underwriters or dealers. For additional information on the
methods of sale, you should refer to the section entitled
Plan of Distribution in this prospectus. If any
underwriters are involved in the sale of any securities with
respect to which this prospectus is being delivered, the names
of such underwriters and any applicable commissions or discounts
and over-allotment options will be set forth in a prospectus
supplement. The price to the public of such securities and the
net proceeds that we expect to receive from such sale will also
be set forth in a prospectus supplement.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this Prospectus
is ,
2006
TABLE OF CONTENTS
You should carefully read both this prospectus and the
applicable prospectus supplement together with the additional
information described under Where You Can Find More
Information before buying securities in this offering. You
should rely only on the information we have provided or
incorporated by reference in this prospectus or any prospectus
supplement. We have not authorized anyone to provide you with
information different from that contained or incorporated by
reference in this prospectus. No dealer, salesperson or other
person is authorized to give any information or to represent
anything not contained or incorporated by reference in this
prospectus. You must not rely on any unauthorized information or
representation. This prospectus is an offer to sell only the
securities offered hereby, but only under circumstances and in
jurisdictions where it is lawful to do so. You should assume
that the information in this prospectus or any prospectus
supplement is accurate only as of the date on the front of the
document and that any information we have incorporated by
reference is accurate only as of the date of the document
incorporated by reference, regardless of the time of delivery of
this prospectus or any sale of a security.
This prospectus contains summaries of certain provisions
contained in some of the documents described herein, but
reference is made to the actual documents for complete
information. All of the summaries are qualified in their
entirety by the actual documents. Copies of some of the
documents referred to herein have been filed or will be filed as
exhibits to the registration statement of which this prospectus
is a part (or will be incorporated by reference from a current
report on Form 8-K
that we file with the SEC), and you may obtain copies of those
documents as described below under Where You Can Find More
Information.
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we
filed with the Securities and Exchange Commission, or SEC, using
a shelf registration process. Under this shelf
registration process, we may offer shares of our common stock
and preferred stock, various series of debt securities and/or
warrants to purchase any of such securities, either individually
or in units, in one or more offerings, with a total value of up
to $100,000,000. This prospectus provides you with a general
description of the securities we may offer. Each time we offer a
type or series of securities under this prospectus, we will
provide a prospectus supplement that will contain more specific
information about the terms of those securities. We may also
add, update or change in a prospectus supplement any of the
information contained in this prospectus or in documents we have
incorporated by reference into this prospectus. However, no
prospectus supplement will fundamentally change the terms that
are set forth in this prospectus or offer a security that is not
registered and described in this prospectus at the time of its
effectiveness. This prospectus, together with the applicable
prospectus supplements and the documents incorporated by
reference into this prospectus, includes all material
information relating to this offering. Please carefully read
both this prospectus and any prospectus supplement together with
the additional information described below under Where You
Can Find More Information. THIS PROSPECTUS MAY NOT BE
USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED
BY A PROSPECTUS SUPPLEMENT.
SOLEXA, INC.
We are in the business of developing and commercializing genetic
analysis technologies. We are currently developing and preparing
to commercialize the Solexa Genome Analysis System, which
performs DNA sequencing based on our proprietary reversible
terminator Sequencing-by-Synthesis, or SBS, chemistry and our
Clonal Single Molecule
Arraytm
technology. This instrument platform is expected to perform a
range of analyses, including whole genome resequencing, gene
expression analysis and small RNA analysis. We believe that this
technology, which can potentially generate over a billion bases
of DNA sequence from a single experiment with a single sample
preparation, will dramatically reduce the cost, and improve the
practicality, of human resequencing relative to conventional
technologies. We expect our first-generation instrument, the
1G Genome Analyzer, to enable human genome resequencing
below $100,000 per sample, which would make it the first
platform to reach this important milestone. We introduced the
1G Genome Analyzer to customers in 2005 and expect to begin
shipping and recognizing revenues on instruments in 2006. Our
longer-term goal is to further reduce the cost of resequencing a
human genome to a few thousand dollars for use in a wide range
of applications from basic research through clinical diagnostics.
We incorporated in the state of Delaware in February 1992. In
March 2005, we completed the combination of our company with
Solexa Limited, a company registered in England and Wales, and
changed our name from Lynx Therapeutics, Inc. to Solexa, Inc.
Our principal executive offices are located at
25861 Industrial Blvd., Hayward, CA 94545. Our telephone
number is (510) 670-9300. Our website address is
http://www.solexa.com. We do not incorporate the information on
our website into this prospectus, and you should not consider it
part of this prospectus.
1
RISK FACTORS
An investment in our securities involves a high degree of risk.
You should consider carefully the risk factors in any prospectus
supplements and in our most recent annual and quarterly filings
with the SEC, as well as other information in this prospectus
and any prospectus supplements and the documents incorporated by
reference herein or therein, before purchasing any of our
securities. Each of the risk factors could adversely affect our
business, operating results and financial condition, as well as
adversely affect the value of an investment in our securities.
THE SECURITIES WE MAY OFFER
We may offer shares of our common stock and preferred stock,
various series of debt securities and/or warrants to purchase
any of such securities, either individually or in units, with a
total value of up to $100,000,000, from time to time under this
prospectus at prices and on terms to be determined by market
conditions at the time of offering. This prospectus provides you
with a general description of the securities we may offer. Each
time we offer a type or series of securities under this
prospectus, we will provide a prospectus supplement that will
describe the specific amounts, prices and other important terms
of the securities, including, to the extent applicable:
|
|
|
|
|
designation or classification; |
|
|
|
aggregate principal amount or aggregate offering price; |
|
|
|
maturity, if applicable; |
|
|
|
rates and times of payment of interest or dividends, if any; |
|
|
|
redemption, conversion or sinking fund terms, if any; |
|
|
|
voting or other rights, if any; |
|
|
|
conversion prices, if any; and |
|
|
|
important United States federal income tax considerations. |
The prospectus supplement also may add, update or change
information contained in this prospectus or in documents we have
incorporated by reference into this prospectus. However, no
prospectus supplement will fundamentally change the terms that
are set forth in this prospectus or offer a security that is not
registered and described in this prospectus at the time of its
effectiveness.
THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF ANY
SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS
SUPPLEMENT.
We may sell the securities directly to investors or to or
through agents, underwriters or dealers. We, and our agents or
underwriters, reserve the right to accept or reject all or part
of any proposed purchase of securities. If we offer securities
through agents or underwriters, we will include in the
applicable prospectus supplement:
|
|
|
|
|
the names of those agents or underwriters; |
|
|
|
applicable fees, discounts and commissions to be paid to them; |
|
|
|
details regarding over-allotment options, if any; and |
|
|
|
the net proceeds to us. |
Common Stock. We may issue shares of our common stock
from time to time. The holders of common stock are entitled to
one vote per share on all matters to be voted upon by
stockholders. Subject to preferences that may be applicable to
any outstanding preferred stock, the holders of common stock are
entitled to receive ratably any dividends that may be declared
from time to time by the board of directors out of funds legally
available for that purpose.
2
Preferred Stock. We may issue shares of our preferred
stock from time to time, in one or more series. Our board of
directors may determine the rights, preferences, privileges and
restrictions of the preferred stock, including dividend rights,
conversion rights, preemptive rights, voting rights, terms of
redemption, liquidation preferences, sinking fund terms and the
number of shares constituting any series or the designation of
any series. Convertible preferred stock will be convertible into
our common stock. Conversion may be mandatory or at your option
and would be at prescribed conversion rates.
If we sell any series of preferred stock under this prospectus
and applicable prospectus supplements, we will fix the rights,
preferences, privileges, qualifications and restrictions of the
preferred stock of such series in the certificate of designation
relating to that series. We will file as an exhibit to the
registration statement of which this prospectus is a part, or
will incorporate by reference from a current report on
Form 8-K that we
file with the SEC, the form of any certificate of designation
that describes the terms of the series of preferred stock we are
offering before the issuance of the related series of preferred
stock. We urge you to read the prospectus supplements related to
the series of preferred stock being offered, as well as the
complete certificate of designation that contains the terms of
the applicable series of preferred stock.
Debt Securities. We may offer debt securities from time
to time, in one or more series, as either senior or subordinated
debt or as senior or subordinated convertible debt. The senior
debt securities will rank equally with any other unsecured and
unsubordinated debt. The subordinated debt securities will be
subordinate and junior in priority of payment to certain of our
other indebtedness to the extent described in a prospectus
supplement. Convertible debt securities will be convertible into
or exchangeable for our common stock or other securities of
ours. Conversion may be mandatory or at your option and would be
at prescribed conversion rates.
The debt securities will be issued under one or more documents
called indentures, which are contracts between us and a national
banking association or other eligible party, as trustee. In this
prospectus, we have summarized certain general features of the
debt securities. We urge you, however, to read the prospectus
supplements related to the series of debt securities being
offered, as well as the complete indentures that contain the
terms of the debt securities. Forms of indentures have been
filed as exhibits to the registration statement of which this
prospectus is a part, and supplemental indentures and forms of
debt securities containing the terms of the debt securities
being offered will be filed as exhibits to the registration
statement of which this prospectus is a part or will be
incorporated by reference from a current report on
Form 8-K that we
file with the SEC.
Warrants. We may issue warrants for the purchase of
common stock, preferred stock and/or debt securities, in one or
more series. We may issue warrants independently or together
with common stock, preferred stock and/or debt securities, and
the warrants may be attached to or separate from these
securities. In this prospectus, we have summarized certain
general features of the warrants. We urge you, however, to read
the prospectus supplements related to the particular series of
warrants being offered, as well as the warrant agreements and
warrant certificates that contain the terms of the warrants.
Forms of the warrant agreements and forms of warrant
certificates containing the terms of the warrants being offered
have been filed as exhibits to the registration statement of
which this prospectus is a part, and supplemental warrant
agreements and forms of warrant certificates will be filed as
exhibits to the registration statement of which this prospectus
is a part or will be incorporated by reference from a current
report on Form 8-K
that we file with the SEC.
We will evidence each series of warrants by warrant certificates
that we will issue under a separate agreement. We will enter
into the warrant agreements with a warrant agent. Each warrant
agent will be a bank or trust company that we select. We will
indicate the name and address of the warrant agent in the
applicable prospectus supplement relating to a particular series
of warrants.
Units. We may issue units consisting of common stock,
preferred stock, debt securities and/or warrants for the
purchase of common stock, preferred stock and/or debt securities
in one or more series. In this prospectus, we have summarized
certain general features of the units. We urge you, however, to
read the prospectus supplements related to the series of units
being offered, as well as the unit agreements that contain the
terms of the units. We will file as exhibits to the registration
statement of which this prospectus is a part,
3
or will incorporate by reference from a current report on
Form 8-K that we
file with the SEC, the form of unit agreement and any
supplemental agreements that describe the terms of the series of
units we are offering before the issuance of the related series
of units.
We will evidence each series of units by unit certificates that
we will issue under a separate agreement. We will enter into the
unit agreements with a unit agent. Each unit agent will be a
bank or trust company that we select. We will indicate the name
and address of the unit agent in the applicable prospectus
supplement relating to a particular series of units.
FORWARD-LOOKING STATEMENTS
This prospectus, including the information that we incorporate
by reference, contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933,
as amended, or the Securities Act, and Section 21E of the
Securities Exchange Act of 1934, as amended, or the Exchange
Act. These statements relate to future events or our future
financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to
differ materially from any future results, levels of activity,
performance or achievements expressed or implied by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as
anticipates, believes,
continues, estimates,
expects, intends, may,
plans, potential, predicts,
should, will, or the negative of these
terms or other comparable terminology. These forward-looking
statements may also use different phrases. Discussions
containing these forward-looking statements may be found, among
other places, in Business and
Managements Discussion and Analysis of Financial
Condition and Results of Operations incorporated by
reference from our most recent annual report on
Form 10-K and in
our most recent quarterly report on
Form 10-Q
subsequent to the filing of our most recent annual report on
Form 10-K with the
SEC, as well as any amendments thereto reflected in subsequent
filings with the SEC. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements and you should not place undue reliance on our
forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make.
Forward-looking statements include, but are not limited to,
statements about:
|
|
|
|
|
our ability to commercialize our Genome Analysis System; |
|
|
|
our ability to achieve the desired technical performance
specifications of our Genome Analysis System; |
|
|
|
our estimates regarding anticipated capital requirements and our
need for additional financing; and |
|
|
|
establishment of our sales and marketing organization. |
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual
results, performance or achievements to differ materially from
any future results, performance or achievements expressed or
implied by such forward-looking statements. These risks include
those risks discussed under the heading Risk Factors
contained in any supplements to this prospectus and in our most
recent annual report on
Form 10-K and any
quarterly reports on
Form 10-Q for
quarters ended subsequent to the filing of our most recent
annual report on
Form 10-K with the
SEC, as well as any amendments thereto reflected in subsequent
filings with the SEC. Because the factors referred to above
could cause actual results or outcomes to differ materially from
those expressed in any forward-looking statements made by us or
on our behalf, you should not place undue reliance on any
forward-looking statements. New factors emerge from time to
time, and it is not possible for us to predict which factors
will arise. In addition, we cannot assess the impact of each
factor on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking
statements. Further, any forward-looking statement speaks only
as of the date on which it is made, and, except as required by
law, we undertake no obligation to publicly revise our
forward-looking statements to reflect events or circumstances
that arise after the date of this prospectus or the prospectus
supplement or the date of documents incorporated by reference in
this prospectus that include forward-looking statements.
4
RATIO OF EARNINGS TO FIXED CHARGES
The following table sets forth our ratio of earnings to fixed
charges for each of the periods presented. Our earnings were
insufficient to cover fixed charges for each of the periods
presented. Because of the deficiency, the ratio information is
not applicable. The extent to which earnings were insufficient
to cover fixed charges is shown below. Amounts shown are in
thousands.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, | |
|
|
| |
|
|
2005 | |
|
2004 | |
|
2003 | |
|
2002 | |
|
2001 | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
Deficiency of earnings available to cover fixed charges
|
|
$ |
(32,681 |
) |
|
$ |
(10,949 |
) |
|
$ |
(6,356 |
) |
|
$ |
(4,761 |
) |
|
$ |
(2,509 |
) |
Ratio of Earnings to Fixed Charges
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
For purposes of computing the deficiency of earnings available
to cover fixed charges, fixed charges represent
(i) interest expensed and capitalized, (ii) amortized
premiums, discounts and capitalized expenses related to
indebtedness, (iii) and an estimate of the portion of
operating lease rental expense that is representative of
interest. Deficiency of earnings consist of loss before income
taxes, plus fixed charges.
USE OF PROCEEDS
Unless otherwise provided in the applicable prospectus
supplement, we intend to use the net proceeds from the sale of
securities under this prospectus for general corporate purposes,
including production and supply activities, sales and marketing
activities, research and development activities, and general and
administrative expenses. We may also use a portion of the net
proceeds to acquire or invest in fixed assets, businesses,
products and technologies that are complementary to our own,
although we currently are not planning or negotiating any such
transactions. We will set forth in the prospectus supplement our
intended use for the net proceeds received from the sale of any
securities. Pending the application of the net proceeds, we
intend to invest the net proceeds in interest-bearing,
investment-grade securities.
DESCRIPTION OF CAPITAL STOCK
General
Our authorized capital stock consists of 60,000,000 shares
of common stock, $0.01 par value, and 2,000,000 shares
of undesignated preferred stock, $0.01 par value. As of
May 15, 2006, there were 36,489,127 shares of common
stock outstanding and no shares of preferred stock outstanding.
The following summary description of our capital stock is based
on the provisions of our restated certificate of incorporation
and bylaws and the applicable provisions of the Delaware General
Corporation Law. This information may not be complete in all
respects and is qualified entirely by reference to the
provisions of our restated certificate of incorporation, bylaws
and the Delaware General Corporation Law. For information on how
to obtain copies of our restated certificate of incorporation
and bylaws, which are exhibits to the registration statement of
which this prospectus forms a part, see Where You Can Find
More Information.
Common Stock
The holders of common stock are entitled to one vote per share
on all matters to be voted upon by the stockholders. Subject to
preferences that may be applicable to any outstanding preferred
stock, the holders of common stock are entitled to receive
ratably any dividends that may be declared from time to time by
the board of directors out of funds legally available for that
purpose. In the event of our liquidation, dissolution or winding
up, the holders of common stock are entitled to share ratably in
all assets remaining after payment of liabilities, subject to
prior distribution rights of preferred stock then outstanding.
The common stock has no preemptive or conversion rights or other
subscription rights. There are no redemption or sinking fund
5
provisions applicable to the common stock. All outstanding
shares of our common stock are, and all shares of common stock
that may be issued under this prospectus will be, fully paid and
non-assessable.
Preferred Stock
Our restated certificate of incorporation provides that our
board of directors has the authority, without further action by
the stockholders, to designate and issue up to
2,000,000 shares of preferred stock in one or more series
and to fix the rights, preferences, privileges and restrictions
of this preferred stock, including dividend rights, conversion
rights, preemptive rights, voting rights, terms of redemption,
liquidation preferences, sinking fund terms and the number of
shares constituting any series or the designation of a series,
without further vote or action by the stockholders. Our board of
directors may also establish from time to time the number of
shares constituting any series of preferred stock, and to
increase or decrease the number of shares of any series
subsequent to the issuance of shares of that series, but not
below the number of shares of any series then outstanding.
We will fix the rights, preferences, privileges and restrictions
of the preferred stock of each series in the certificate of
designation relating to that series. We will file as an exhibit
to the registration statement of which this prospectus is a
part, or will incorporate by reference from a current report on
Form 8-K that we
file with the SEC, the form of any certificate of designation
that describes the terms of the series of preferred stock we are
offering before the issuance of the related series of preferred
stock. This description will include:
|
|
|
|
|
the title and stated value; |
|
|
|
the number of shares we are offering; |
|
|
|
the liquidation preference per share; |
|
|
|
the purchase price; |
|
|
|
the dividend rate, period and payment date and method of
calculation for dividends; |
|
|
|
whether dividends will be cumulative or non-cumulative and, if
cumulative, the date from which dividends will accumulate; |
|
|
|
the procedures for any auction and remarketing, if any; |
|
|
|
the provisions for a sinking fund, if any; |
|
|
|
the provisions for redemption or repurchase, if applicable, and
any restrictions on our ability to exercise those redemption and
repurchase rights; |
|
|
|
any listing of the preferred stock on any securities exchange or
market; |
|
|
|
whether the preferred stock will be convertible into our common
stock, and, if applicable, the conversion price, or how it will
be calculated, and the conversion period; |
|
|
|
whether the preferred stock will be exchangeable into debt
securities, and, if applicable, the exchange price, or how it
will be calculated, and the exchange period; |
|
|
|
voting rights, if any, of the preferred stock; |
|
|
|
preemption rights, if any; |
|
|
|
restrictions on transfer, sale or other assignment, if any; |
|
|
|
whether interests in the preferred stock will be represented by
depositary shares; |
|
|
|
a discussion of any material or special United States federal
income tax considerations applicable to the preferred stock; |
|
|
|
the relative ranking and preferences of the preferred stock as
to dividend rights and rights if we liquidate, dissolve or wind
up our affairs; |
6
|
|
|
|
|
any limitations on issuance of any class or series of preferred
stock ranking senior to or on a parity with the series of
preferred stock as to dividend rights and rights if we
liquidate, dissolve or wind up our affairs; and |
|
|
|
any other specific terms, preferences, rights or limitations of,
or restrictions on, the preferred stock. |
If we issue shares of preferred stock under this prospectus, the
shares will be fully paid and non-assessable and will not have,
or be subject to, any preemptive or similar rights.
The General Corporation Law of the State of Delaware, the state
of our incorporation, provides that the holders of preferred
stock will have the right to vote separately as a class on any
proposal involving fundamental changes in the rights of holders
of that preferred stock. This right is in addition to any voting
rights that may be provided for in the applicable certificate of
designation.
The issuance of preferred stock could adversely affect the
voting power, liquidation rights, conversion or other rights of
holders of common stock. Preferred stock could be issued quickly
with terms designed to delay or prevent a change in control of
our company or make removal of management more difficult.
Additionally, the issuance of preferred stock may have the
effect of decreasing the market price of our common stock.
Anti-Takeover Provisions
Certain provisions of Delaware law and our restated certificate
of incorporation and bylaws could make the acquisition of our
company through a tender offer, a proxy contest or other means
more difficult and could make the removal of incumbent officers
and directors more difficult. We expect these provisions to
discourage certain types of coercive takeover practices and
inadequate takeover bids and to encourage persons seeking to
acquire control of our company to first negotiate with our board
of directors. We believe that the benefits provided by our
ability to negotiate with the proponent of an unfriendly or
unsolicited proposal outweigh the disadvantages of discouraging
these proposals. We believe the negotiation of an unfriendly or
unsolicited proposal could result in an improvement of its terms.
We are subject to Section 203 of the General Corporation
Law of the State of Delaware, an anti-takeover law. In general,
Section 203 prohibits a publicly held Delaware corporation
from engaging in a business combination with an
interested stockholder for a period of three years
following the date the person became an interested stockholder
unless:
|
|
|
|
|
the board of directors of the corporation approved either the
business combination or the transaction in which the person
became an interested stockholder prior to the date the person
attained this status; |
|
|
|
upon completion of the transaction that resulted in the person
becoming an interested stockholder, the stockholder owned at
least 85% of our voting stock of the corporation outstanding at
the time the transaction commenced, excluding for purposes of
determining the number of shares outstanding (1) shares
owned by persons who are directors and also officers and
(2) shares issued under employee stock plans under which
employee participants do not have the right to determine
confidentially whether shares held subject to the plan will be
tendered in a tender or exchange offer; or |
|
|
|
on or subsequent to the date the person became an interested
stockholder, the board of directors approved the business
combination and the stockholders other than the interested
stockholder authorized the transaction at an annual or special
meeting of stockholders, and not by written consent, by the
affirmative vote of at least
662/3
% of the outstanding voting stock not owned by the
interested stockholder. |
Generally, a business combination includes a merger, asset or
stock sale, or other transaction resulting in a financial
benefit to the interested stockholder. An interested stockholder
is a person who, together with its affiliates and associates,
owns, or if such person is an affiliate or associate of our
company, did own within three years prior to the determination
of interested stockholder status, 15% or more of a
corporations outstanding voting securities. We expect the
existence of this provision to have an anti-takeover effect with
7
respect to transactions our board of directors does not approve
in advance. We also anticipate that Section 203 may also
discourage attempts that might result in the payment of a
premium over the market price for the shares of common stock
held by stockholders.
|
|
|
Certificate of Incorporation and Bylaws Provisions |
Our bylaws establish an advance notice procedure for stockholder
proposals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for
election to the board of directors. At an annual meeting,
stockholders may only consider proposals or nominations
specified in the notice of meeting or brought before the meeting
by or at the direction of the board of directors. Stockholders
may also consider a proposal or nomination by a person who was a
stockholder of record on the record date for the meeting and on
the date that notice of the proposal or nomination was given,
who is entitled to vote at the meeting and who has given to our
secretary timely written notice, in proper form, of his or her
intention to bring that business before the meeting. The bylaws
do not give the board of directors the power to approve or
disapprove stockholder nominations of candidates or proposals
regarding other business to be conducted at a special or annual
meeting of the stockholders. However, our bylaws may have the
effect of precluding the conduct of certain business at a
meeting if the proper procedures are not followed. These
provisions may also discourage or deter a potential acquirer
from conducting a solicitation of proxies to elect the
acquirers own slate of directors or otherwise attempting
to obtain control of our company.
Under Delaware law, a special meeting of stockholders may be
called by the board of directors or by any other person
authorized to do so in the certificate of incorporation or the
bylaws. Our restated certificate of incorporation and bylaws
provide a special meeting of the stockholders may be called by
the chairman of the board of directors, the president, the board
of directors pursuant to a resolution adopted by a majority of
the total number of authorized directors (whether or not there
exist any vacancies in previously authorized directorships at
the time any such resolution is presented to the Board for
adoption) or by the holders of shares entitled to cast not less
than ten percent (10%) of the votes at the meeting.
Our restated certificate of incorporation and our bylaws permit
our board to increase its size and to fill the resulting
vacancies as well as to issue preferred stock, see
Description of Capital Stock Preferred
Stock, which our board may use to thwart a hostile
takeover attempt.
National Market Listing
Our common stock is quoted on the NASDAQ Global Market under the
symbol SLXA.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is
Computershare, located at 150 Royall Street, Canton,
Massachusetts 02021. The transfer agent for any series of
preferred stock will be named and described in the prospectus
supplement for that series.
DESCRIPTION OF DEBT SECURITIES
The following description, together with the additional
information we include in any applicable prospectus supplements,
summarizes the material terms and provisions of the debt
securities that we may offer under this prospectus. While the
terms we have summarized below will apply generally to any
future debt securities that we may offer under this prospectus,
we will describe the particular terms of any debt securities
that we may offer in more detail in the applicable prospectus
supplement. The terms of any debt securities we offer under a
prospectus supplement may differ from the terms we describe
below. However, no prospectus supplement will fundamentally
change the terms that are set forth in this prospectus or offer
a security that is not registered and described in this
prospectus at the time of its effectiveness.
We will issue the senior debt securities under the senior
indenture that we will enter into with the trustee to be named
in the senior indenture. We will issue the subordinated debt
securities under the subordinated indenture that we will enter
into with the trustee to be named in the subordinated indenture.
We have filed
8
forms of these documents as exhibits to the registration
statement of which this prospectus is a part. We use the term
indentures in this prospectus to refer to both the
senior indenture and the subordinated indenture.
The indentures will be qualified under the Trust Indenture Act
of 1939. We use the term debenture trustee to refer
to either the trustee under the senior indenture or the trustee
under the subordinated indenture, as applicable.
The following summaries of material provisions of the senior
debt securities, the subordinated debt securities and the
indentures are subject to, and qualified in their entirety by
reference to, all the provisions of the indenture applicable to
a particular series of debt securities. We urge you to read the
applicable prospectus supplements related to the debt securities
that we sell under this prospectus, as well as the indenture
that contains the terms of the debt securities. Except as we may
otherwise indicate, the terms of the senior indenture and the
subordinated indenture are identical.
General
We will describe in each prospectus supplement the following
terms relating to a series of debt securities:
|
|
|
|
|
the title; |
|
|
|
the principal amount being offered, and if a series, the total
amount authorized and the total amount outstanding; |
|
|
|
any limit on the amount that may be issued; |
|
|
|
whether or not we will issue the series of debt securities in
global form, the terms and who the depositary will be; |
|
|
|
the maturity date; |
|
|
|
whether and under what circumstances, if any, we will pay
additional amounts on any debt securities held by a person who
is not a United States person for tax purposes, and whether we
can redeem the debt securities if we have to pay such additional
amounts; |
|
|
|
the annual interest rate, which may be fixed or variable, or the
method for determining the rate and the date interest will begin
to accrue, the dates interest will be payable and the regular
record dates for interest payment dates or the method for
determining such dates; |
|
|
|
whether or not the debt securities will be secured or unsecured,
and the terms of any secured debt; |
|
|
|
the terms of the subordination of any series of subordinated
debt; |
|
|
|
the place where payments will be payable; |
|
|
|
restrictions on transfer, sale or other assignment, if any; |
|
|
|
our right, if any, to defer payment of interest and the maximum
length of any such deferral period; |
|
|
|
the date, if any, after which, and the price at which, we may,
at our option, redeem the series of debt securities pursuant to
any optional or provisional redemption provisions and the terms
of those redemption provisions; |
|
|
|
the date, if any, on which, and the price at which we are
obligated, pursuant to any mandatory sinking fund or analogous
fund provisions or otherwise, to redeem, or at the holders
option to purchase, the series of debt securities and the
currency or currency unit in which the debt securities are
payable; |
|
|
|
whether the indenture will restrict our ability and/or the
ability of our subsidiaries to: |
|
|
|
|
|
incur additional indebtedness; |
|
|
|
issue additional securities; |
|
|
|
create liens; |
9
|
|
|
|
|
pay dividends and make distributions in respect of our capital
stock and the capital stock of our subsidiaries; |
|
|
|
redeem capital stock; |
|
|
|
place restrictions on our subsidiaries ability to pay
dividends, make distributions or transfer assets; |
|
|
|
make investments or other restricted payments; |
|
|
|
sell or otherwise dispose of assets; |
|
|
|
enter into sale-leaseback transactions; |
|
|
|
engage in transactions with stockholders and affiliates; |
|
|
|
issue or sell stock of our subsidiaries; or |
|
|
|
effect a consolidation or merger; |
|
|
|
|
|
whether the indenture will require us to maintain any interest
coverage, fixed charge, cash flow-based, asset based or other
financial ratios; |
|
|
|
a discussion of any material or special United States federal
income tax considerations applicable to the debt securities; |
|
|
|
information describing any book-entry features; |
|
|
|
provisions for a sinking fund purchase or other analogous fund,
if any; |
|
|
|
the applicability of the provisions in the indenture on
discharge; |
|
|
|
whether the debt securities are to be offered at a price such
that they will be deemed to be offered at an original
issue discount as defined in paragraph (a) of
Section 1273 of the Internal Revenue Code; |
|
|
|
the denominations in which we will issue the series of debt
securities, if other than denominations of $1,000 and any
integral multiple thereof; |
|
|
|
the currency of payment of debt securities if other than
U.S. dollars and the manner of determining the equivalent
amount in U.S. dollars; and |
|
|
|
any other specific terms, preferences, rights or limitations of,
or restrictions on, the debt securities, including any
additional events of default or covenants provided with respect
to the debt securities, and any terms that may be required by us
or advisable under applicable laws or regulations. |
Conversion or Exchange Rights
We will set forth in the prospectus supplement the terms on
which a series of debt securities may be convertible into or
exchangeable for our common stock or our other securities. We
will include provisions as to whether conversion or exchange is
mandatory, at the option of the holder or at our option. We may
include provisions pursuant to which the number of shares of our
common stock or our other securities that the holders of the
series of debt securities receive would be subject to adjustment.
Consolidation, Merger or Sale
The indentures will not contain any covenant that restricts our
ability to merge or consolidate, or sell, convey, transfer or
otherwise dispose of all or substantially all of our assets.
However, any successor to or acquirer of such assets must assume
all of our obligations under the indentures or the debt
securities, as appropriate. If the debt securities are
convertible for our other securities or securities of other
entities, the person with whom we consolidate or merge or to
whom we sell all of our property must make provisions for the
conversion of the debt securities into securities that the
holders of the debt securities would have received if they had
converted the debt securities before the consolidation, merger
or sale.
10
Events of Default Under the Indenture
The following are events of default under the indentures with
respect to any series of debt securities that we may issue:
|
|
|
|
|
if we fail to pay interest when due and payable and our failure
continues for 90 days and the time for payment has not been
extended or deferred; |
|
|
|
if we fail to pay the principal, premium or sinking fund
payment, if any, when due and payable and the time for payment
has not been extended or delayed; |
|
|
|
if we fail to observe or perform any other covenant contained in
the debt securities or the indentures, other than a covenant
specifically relating to another series of debt securities, and
our failure continues for 90 days after we receive notice
from the debenture trustee or holders of at least 25% in
aggregate principal amount of the outstanding debt securities of
the applicable series; and |
|
|
|
if specified events of bankruptcy, insolvency or reorganization
occur. |
If an event of default with respect to debt securities of any
series occurs and is continuing, other than an event of default
specified in the last bullet point above, the debenture trustee
or the holders of at least 25% in aggregate principal amount of
the outstanding debt securities of that series, by notice to us
in writing, and to the debenture trustee if notice is given by
such holders, may declare the unpaid principal of, premium, if
any, and accrued interest, if any, due and payable immediately.
If an event of default specified in the last bullet point above
occurs with respect to us, the principal amount of and accrued
interest, if any, of each issue of debt securities then
outstanding shall be due and payable without any notice or other
action on the part of the debenture trustee or any holder.
The holders of a majority in principal amount of the outstanding
debt securities of an affected series may waive any default or
event of default with respect to the series and its
consequences, except defaults or events of default regarding
payment of principal, premium, if any, or interest, unless we
have cured the default or event of default in accordance with
the indenture. Any waiver shall cure the default or event of
default.
Subject to the terms of the indentures, if an event of default
under an indenture shall occur and be continuing, the debenture
trustee will be under no obligation to exercise any of its
rights or powers under such indenture at the request or
direction of any of the holders of the applicable series of debt
securities, unless such holders have offered the debenture
trustee reasonable indemnity. The holders of a majority in
principal amount of the outstanding debt securities of any
series will have the right to direct the time, method and place
of conducting any proceeding for any remedy available to the
debenture trustee, or exercising any trust or power conferred on
the debenture trustee, with respect to the debt securities of
that series, provided that:
|
|
|
|
|
the direction so given by the holder is not in conflict with any
law or the applicable indenture; and |
|
|
|
subject to its duties under the Trust Indenture Act of 1939, the
debenture trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the
holders not involved in the proceeding. |
A holder of the debt securities of any series will only have the
right to institute a proceeding under the indentures or to
appoint a receiver or trustee, or to seek other remedies if:
|
|
|
|
|
the holder has given written notice to the debenture trustee of
a continuing event of default with respect to that series; |
|
|
|
the holders of at least 25% in aggregate principal amount of the
outstanding debt securities of that series have made written
request, and such holders have offered reasonable indemnity to
the debenture trustee to institute the proceeding as
trustee; and |
|
|
|
the debenture trustee does not institute the proceeding, and
does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that
series other conflicting directions within 90 days after
the notice, request and offer. |
11
These limitations do not apply to a suit instituted by a holder
of debt securities if we default in the payment of the
principal, premium, if any, or interest on, the debt securities.
We will periodically file statements with the debenture trustee
regarding our compliance with specified covenants in the
indentures.
Modification of Indenture; Waiver
We and the debenture trustee may change an indenture without the
consent of any holders with respect to specific matters:
|
|
|
|
|
to fix any ambiguity, defect or inconsistency in the indenture; |
|
|
|
to comply with the provisions described above under
Consolidation, Merger or Sale; |
|
|
|
to provide for uncertificated debt securities in addition to or
in place of certificated debt securities; |
|
|
|
to add to our covenants such new covenants, restrictions,
conditions or provisions for the protection of the holders, and
to make the occurrence, or the occurrence and the continuance,
of a default in any such additional covenants, restrictions,
conditions or provisions an event of default; |
|
|
|
to add to, delete from or revise the conditions, limitations,
and restrictions on the authorized amount, terms, or purposes of
issue, authentication and delivery of debt securities, as set
forth in the indenture; |
|
|
|
to change anything that does not materially adversely affect the
interests of any holder of debt securities of any series; |
|
|
|
to provide for the issuance of and establish the form and terms
and conditions of the debt securities of any series as provided
under General to establish the form of any
certifications required to be furnished pursuant to the terms of
the indenture or any series of debt securities, or to add to the
rights of the holders of any series of debt securities; |
|
|
|
to evidence and provide for the acceptance of appointment
hereunder by a successor trustee; or |
|
|
|
to comply with any requirements of the SEC in connection with
the qualification of any indenture under the Trust Indenture Act
of 1939. |
In addition, under the indentures, the rights of holders of a
series of debt securities may be changed by us and the debenture
trustee with the written consent of the holders of at least a
majority in aggregate principal amount of the outstanding debt
securities of each series that is affected. However, we and the
debenture trustee may only make the following changes with the
consent of each holder of any outstanding debt securities
affected:
|
|
|
|
|
extending the fixed maturity of the series of debt securities; |
|
|
|
reducing the principal amount, reducing the rate of or extending
the time of payment of interest, or reducing any premium payable
upon the redemption of any debt securities; or |
|
|
|
reducing the percentage of debt securities, the holders of which
are required to consent to any amendment, supplement,
modification or waiver. |
Discharge
Each indenture provides that we can elect to be discharged from
our obligations with respect to one or more series of debt
securities, except for specified obligations, including
obligations to:
|
|
|
|
|
register the transfer or exchange of debt securities of the
series; |
|
|
|
replace stolen, lost or mutilated debt securities of the series; |
|
|
|
maintain paying agencies; |
|
|
|
hold monies for payment in trust; |
12
|
|
|
|
|
compensate and indemnify the debenture trustee; |
|
|
|
appoint any successor trustee; and |
|
|
|
recover excess money held by the debenture trustee. |
In order to exercise our rights to be discharged, we must
deposit with the debenture trustee money or government
obligations sufficient to pay all the principal of, any premium,
if any, and interest on, the debt securities of the series on
the dates payments are due.
Form, Exchange and Transfer
We will issue the debt securities of each series only in fully
registered form without coupons and, unless we otherwise specify
in the applicable prospectus supplement, in denominations of
$1,000 and any integral multiple thereof. The indentures provide
that we may issue debt securities of a series in temporary or
permanent global form and as book-entry securities that will be
deposited with, or on behalf of, The Depository Trust Company or
another depositary named by us and identified in a prospectus
supplement with respect to that series. See Legal
Ownership of Securities for a further description of the
terms relating to any book-entry securities.
At the option of the holder, subject to the terms of the
indentures and the limitations applicable to global securities
described in the applicable prospectus supplement, the holder of
the debt securities of any series can exchange the debt
securities for other debt securities of the same series, in any
authorized denomination and of like tenor and aggregate
principal amount.
Subject to the terms of the indentures and the limitations
applicable to global securities set forth in the applicable
prospectus supplement, holders of the debt securities may
present the debt securities for exchange or for registration of
transfer, duly endorsed or with the form of transfer endorsed
thereon duly executed if so required by us or the security
registrar, at the office of the security registrar or at the
office of any transfer agent designated by us for this purpose.
Unless otherwise provided in the debt securities that the holder
presents for transfer or exchange, we will make no service
charge for any registration of transfer or exchange, but we may
require payment of any taxes or other governmental charges.
We will name in the applicable prospectus supplement the
security registrar, and any transfer agent in addition to the
security registrar, that we initially designate for any debt
securities. We may at any time designate additional transfer
agents or rescind the designation of any transfer agent or
approve a change in the office through which any transfer agent
acts, except that we will be required to maintain a transfer
agent in each place of payment for the debt securities of each
series.
If we elect to redeem the debt securities of any series, we will
not be required to:
|
|
|
|
|
issue, register the transfer of, or exchange any debt securities
of that series during a period beginning at the opening of
business 15 days before the day of mailing of a notice of
redemption of any debt securities that may be selected for
redemption and ending at the close of business on the day of the
mailing; or |
|
|
|
register the transfer of or exchange any debt securities so
selected for redemption, in whole or in part, except the
unredeemed portion of any debt securities we are redeeming in
part. |
Information Concerning the Debenture Trustee
The debenture trustee, other than during the occurrence and
continuance of an event of default under an indenture,
undertakes to perform only those duties as are specifically set
forth in the applicable indenture. Upon an event of default
under an indenture, the debenture trustee must use the same
degree of care as a prudent person would exercise or use in the
conduct of his or her own affairs. Subject to this provision,
the debenture trustee is under no obligation to exercise any of
the powers given it by the indentures at the request of any
holder of debt securities unless it is offered reasonable
security and indemnity against the costs, expenses and
liabilities that it might incur.
13
Payment and Paying Agents
Unless we otherwise indicate in the applicable prospectus
supplement, we will make payment of the interest on any debt
securities on any interest payment date to the person in whose
name the debt securities, or one or more predecessor securities,
are registered at the close of business on the regular record
date for the interest.
We will pay principal of and any premium and interest on the
debt securities of a particular series at the office of the
paying agents designated by us, except that unless we otherwise
indicate in the applicable prospectus supplement, we will make
interest payments by check that we will mail to the holder or by
wire transfer to certain holders. Unless we otherwise indicate
in a prospectus supplement, we will designate the corporate
trust office of the debenture trustee in the City of New York as
our sole paying agent for payments with respect to debt
securities of each series. We will name in the applicable
prospectus supplement any other paying agents that we initially
designate for the debt securities of a particular series. We
will maintain a paying agent in each place of payment for the
debt securities of a particular series.
All money we pay to a paying agent or the debenture trustee for
the payment of the principal of or any premium or interest on
any debt securities that remains unclaimed at the end of two
years after such principal, premium or interest has become due
and payable will be repaid to us, and the holder of the debt
security thereafter may look only to us for payment thereof.
Governing Law
The indentures and the debt securities will be governed by and
construed in accordance with the laws of the State of New York,
except to the extent that the Trust Indenture Act of 1939 is
applicable.
Subordination of Subordinated Debt Securities
The subordinated debt securities will be unsecured and will be
subordinate and junior in priority of payment to certain of our
other indebtedness to the extent described in a prospectus
supplement. The subordinated indenture does not limit the amount
of subordinated debt securities that we may issue. It also does
not limit us from issuing any other secured or unsecured debt.
DESCRIPTION OF WARRANTS
The following description, together with the additional
information we may include in any applicable prospectus
supplements, summarizes the material terms and provisions of the
warrants that we may offer under this prospectus. While the
terms we have summarized below will apply generally to any
warrants that we may offer under this prospectus, we will
describe the particular terms of any series of warrants in more
detail in the applicable prospectus supplement. The terms of any
warrants offered under a prospectus supplement may differ from
the terms described below. However, no prospectus supplement
will fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and
described in this prospectus at the time of its effectiveness.
We have filed forms of the warrant agreements and forms of
warrant certificates containing the terms of the warrants being
offered as exhibits to the registration statement of which this
prospectus is a part. We will file as exhibits to the
registration statement of which this prospectus is a part, or
will incorporate by reference from a current report on
Form 8-K that we
file with the SEC, the form of warrant agreement, including a
form of warrant certificate, that describes the terms of the
particular series of warrants we are offering before the
issuance of the related series of warrants. The following
summaries of material provisions of the warrants and the warrant
agreements are subject to, and qualified in their entirety by
reference to, all the provisions of the warrant agreement and
warrant certificate applicable to a particular series of
warrants. We urge you to read the applicable prospectus
supplements related to the particular series of warrants that we
sell under this prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of
the warrants.
14
General
We will describe in the applicable prospectus supplement the
terms of the series of warrants, including:
|
|
|
|
|
the offering price and aggregate number of warrants offered; |
|
|
|
the currency for which the warrants may be purchased; |
|
|
|
if applicable, the designation and terms of the securities with
which the warrants are issued and the number of warrants issued
with each such security or each principal amount of such
security; |
|
|
|
if applicable, the date on and after which the warrants and the
related securities will be separately transferable; |
|
|
|
in the case of warrants to purchase debt securities, the
principal amount of debt securities purchasable upon exercise of
one warrant and the price at, and currency in which, this
principal amount of debt securities may be purchased upon such
exercise; |
|
|
|
in the case of warrants to purchase common stock or preferred
stock, the number of shares of common stock or preferred stock,
as the case may be, purchasable upon the exercise of one warrant
and the price at which these shares may be purchased upon such
exercise; |
|
|
|
the effect of any merger, consolidation, sale or other
disposition of our business on the warrant agreements and the
warrants; |
|
|
|
the terms of any rights to redeem or call the warrants; |
|
|
|
any provisions for changes to or adjustments in the exercise
price or number of securities issuable upon exercise of the
warrants; |
|
|
|
the dates on which the right to exercise the warrants will
commence and expire; |
|
|
|
the manner in which the warrant agreements and warrants may be
modified; |
|
|
|
a discussion of any material or special United States federal
income tax consequences of holding or exercising the warrants; |
|
|
|
the amount of warrants outstanding; |
|
|
|
the terms of the securities issuable upon exercise of the
warrants; and |
|
|
|
any other specific terms, preferences, rights or limitations of
or restrictions on the warrants. |
Before exercising their warrants, holders of warrants will not
have any of the rights of holders of the securities purchasable
upon such exercise, including:
|
|
|
|
|
in the case of warrants to purchase debt securities, the right
to receive payments of principal of, or premium, if any, or
interest on, the debt securities purchasable upon exercise or to
enforce covenants in the applicable indenture; or |
|
|
|
in the case of warrants to purchase common stock or preferred
stock, the right to receive dividends, if any, or, payments upon
our liquidation, dissolution or winding up or to exercise voting
rights, if any. |
Exercise of Warrants
Each warrant will entitle the holder to purchase the securities
that we specify in the applicable prospectus supplement at the
exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the
warrants at any time up to the specified time on the expiration
date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised
warrants will become void.
Holders of the warrants may exercise the warrants by delivering
the warrant certificate representing the warrants to be
exercised together with specified information, and paying the
required amount to the warrant
15
agent in immediately available funds, as provided in the
applicable prospectus supplement. We will set forth on the
reverse side of the warrant certificate and in the applicable
prospectus supplement the information that the holder of the
warrant will be required to deliver to the warrant agent.
Upon receipt of the required payment and the warrant certificate
properly completed and duly executed at the corporate trust
office of the warrant agent or any other office indicated in the
applicable prospectus supplement, we will issue and deliver the
securities purchasable upon such exercise. If fewer than all of
the warrants represented by the warrant certificate are
exercised, then we will issue a new warrant certificate for the
remaining amount of warrants. If we so indicate in the
applicable prospectus supplement, holders of the warrants may
surrender securities as all or part of the exercise price for
warrants.
Governing Law
The warrants and warrant agreements will be governed by and
construed in accordance with the laws of the State of New York.
Enforceability of Rights by Holders of Warrants
Each warrant agent will act solely as our agent under the
applicable warrant agreement and will not assume any obligation
or relationship of agency or trust with any holder of any
warrant. A single bank or trust company may act as warrant agent
for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the
applicable warrant agreement or warrant, including any duty or
responsibility to initiate any proceedings at law or otherwise,
or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder
of any other warrant, enforce by appropriate legal action its
right to exercise, and receive the securities purchasable upon
exercise of, its warrants.
Outstanding Warrants
As of May 10, 2006, there were outstanding warrants to
purchase 7,928,209 shares of our common stock. The
exercise prices of these warrants is between $5.00 and
$79.52 per share. The warrants will expire between
May 24, 2006 and January 19, 2011, unless earlier
exercised.
DESCRIPTION OF UNITS
The following description, together with the additional
information we may include in any applicable prospectus
supplements, summarizes the material terms and provisions of the
units that we may offer under this prospectus. While the terms
we have summarized below will apply generally to any units that
we may offer under this prospectus, we will describe the
particular terms of any series of units in more detail in the
applicable prospectus supplement. The terms of any units offered
under a prospectus supplement may differ from the terms
described below. However, no prospectus supplement will
fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and
described in this prospectus at the time of its effectiveness.
We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from
a current report on
Form 8-K that we
file with the SEC, the form of unit agreement that describes the
terms of the series of units we are offering, and any
supplemental agreements, before the issuance of the related
series of units. The following summaries of material terms and
provisions of the units are subject to, and qualified in their
entirety by reference to, all the provisions of the unit
agreement and any supplemental agreements applicable to a
particular series of units. We urge you to read the applicable
prospectus supplements related to the particular series of units
that we sell under this prospectus, as well as the complete unit
agreement and any supplemental agreements that contain the terms
of the units.
16
General
We may issue units comprised of one or more debt securities,
shares of common stock, shares of preferred stock and warrants
in any combination. Each unit will be issued so that the holder
of the unit is also the holder of each security included in the
unit. Thus, the holder of a unit will have the rights and
obligations of a holder of each included security. The unit
agreement under which a unit is issued may provide that the
securities included in the unit may not be held or transferred
separately, at any time or at any time before a specified date.
We will describe in the applicable prospectus supplement the
terms of the series of units, including:
|
|
|
|
|
the designation and terms of the units and of the securities
comprising the units, including whether and under what
circumstances those securities may be held or transferred
separately; |
|
|
|
any provisions of the governing unit agreement that differ from
those described below; and |
|
|
|
any provisions for the issuance, payment, settlement, transfer
or exchange of the units or of the securities comprising the
units. |
The provisions described in this section, as well as those
described under Description of Capital Stock,
Description of Debt Securities and Description
of Warrants will apply to each unit and to any common
stock, preferred stock, debt security or warrant included in
each unit, respectively.
Issuance in Series
We may issue units in such amounts and in numerous distinct
series as we determine.
Enforceability of Rights by Holders of Units
Each unit agent will act solely as our agent under the
applicable unit agreement and will not assume any obligation or
relationship of agency or trust with any holder of any unit. A
single bank or trust company may act as unit agent for more than
one series of units. A unit agent will have no duty or
responsibility in case of any default by us under the applicable
unit agreement or unit, including any duty or responsibility to
initiate any proceedings at law or otherwise, or to make any
demand upon us. Any holder of a unit may, without the consent of
the related unit agent or the holder of any other unit, enforce
by appropriate legal action its rights as holder under any
security included in the unit.
Title
We, the unit agents and any of their agents may treat the
registered holder of any unit certificate as an absolute owner
of the units evidenced by that certificate for any purpose and
as the person entitled to exercise the rights attaching to the
units so requested, despite any notice to the contrary. See
Legal Ownership of Securities.
LEGAL OWNERSHIP OF SECURITIES
We can issue securities in registered form or in the form of one
or more global securities. We describe global securities in
greater detail below. We refer to those persons who have
securities registered in their own names on the books that we or
any applicable trustee or warrant agent maintain for this
purpose as the holders of those securities. These
persons are the legal holders of the securities. We refer to
those persons who, indirectly through others, own beneficial
interests in securities that are not registered in their own
names, as indirect holders of those securities. As
we discuss below, indirect holders are not legal holders, and
investors in securities issued in book-entry form or in street
name will be indirect holders.
Book-Entry Holders
We may issue securities in book-entry form only, as we will
specify in the applicable prospectus supplement. This means
securities may be represented by one or more global securities
registered in the name
17
of a financial institution that holds them as depositary on
behalf of other financial institutions that participate in the
depositarys book-entry system. These participating
institutions, which are referred to as participants, in turn,
hold beneficial interests in the securities on behalf of
themselves or their customers.
Only the person in whose name a security is registered is
recognized as the holder of that security. Securities issued in
global form will be registered in the name of the depositary or
its nominee. Consequently, for securities issued in global form,
we will recognize only the depositary as the holder of the
securities, and we will make all payments on the securities to
the depositary. The depositary passes along the payments it
receives to its participants, which in turn pass the payments
along to their customers who are the beneficial owners. The
depositary and its participants do so under agreements they have
made with one another or with their customers; they are not
obligated to do so under the terms of the securities.
As a result, investors in a book-entry security will not own
securities directly. Instead, they will own beneficial interests
in a global security, through a bank, broker or other financial
institution that participates in the depositarys
book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will
be indirect holders, and not holders, of the securities.
Street Name Holders
We may terminate a global security or issue securities in
non-global form. In these cases, investors may choose to hold
their securities in their own names or in street
name. Securities held by an investor in street name would
be registered in the name of a bank, broker or other financial
institution that the investor chooses, and the investor would
hold only a beneficial interest in those securities through an
account he or she maintains at that institution.
For securities held in street name, we will recognize only the
intermediary banks, brokers and other financial institutions in
whose names the securities are registered as the holders of
those securities, and we will make all payments on those
securities to them. These institutions pass along the payments
they receive to their customers who are the beneficial owners,
but only because they agree to do so in their customer
agreements or because they are legally required to do so.
Investors who hold securities in street name will be indirect
holders, not holders, of those securities.
Legal Holders
Our obligations, as well as the obligations of any applicable
trustee and of any third parties employed by us or a trustee,
run only to the legal holders of the securities. We do not have
obligations to investors who hold beneficial interests in global
securities, in street name or by any other indirect means. This
will be the case whether an investor chooses to be an indirect
holder of a security or has no choice because we are issuing the
securities only in global form.
For example, once we make a payment or give a notice to the
holder, we have no further responsibility for the payment or
notice even if that holder is required, under agreements with
depositary participants or customers or by law, to pass it along
to the indirect holders but does not do so. Similarly, we may
want to obtain the approval of the holders to amend an
indenture, to relieve us of the consequences of a default or of
our obligation to comply with a particular provision of the
indenture or for other purposes. In such an event, we would seek
approval only from the holders, and not the indirect holders, of
the securities. Whether and how the holders contact the indirect
holders is up to the holders.
Special Considerations for Indirect Holders
If you hold securities through a bank, broker or other financial
institution, either in book-entry form or in street name, you
should check with your own institution to find out:
|
|
|
|
|
how it handles securities payments and notices; |
|
|
|
whether it imposes fees or charges; |
|
|
|
how it would handle a request for the holders consent, if
ever required; |
18
|
|
|
|
|
whether and how you can instruct it to send you securities
registered in your own name so you can be a holder, if that is
permitted in the future; |
|
|
|
how it would exercise rights under the securities if there were
a default or other event triggering the need for holders to act
to protect their interests; and |
|
|
|
if the securities are in book-entry form, how the
depositarys rules and procedures will affect these matters. |
Global Securities
A global security is a security that represents one or any other
number of individual securities held by a depositary. Generally,
all securities represented by the same global securities will
have the same terms.
Each security issued in book-entry form will be represented by a
global security that we deposit with and register in the name of
a financial institution or its nominee that we select. The
financial institution that we select for this purpose is called
the depositary. Unless we specify otherwise in the applicable
prospectus supplement, The Depository Trust Company, New York,
New York, known as DTC, will be the depositary for all
securities issued in book-entry form.
A global security may not be transferred to or registered in the
name of anyone other than the depositary, its nominee or a
successor depositary, unless special termination situations
arise. We describe those situations below under Special
Situations When a Global Security Will Be Terminated. As a
result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and holder of all securities
represented by a global security, and investors will be
permitted to own only beneficial interests in a global security.
Beneficial interests must be held by means of an account with a
broker, bank or other financial institution that in turn has an
account with the depositary or with another institution that
does. Thus, an investor whose security is represented by a
global security will not be a holder of the security, but only
an indirect holder of a beneficial interest in the global
security.
If the prospectus supplement for a particular security indicates
that the security will be issued in global form only, then the
security will be represented by a global security at all times
unless and until the global security is terminated. If
termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no
longer be held through any book-entry clearing system.
Special Considerations for Global Securities
As an indirect holder, an investors rights relating to a
global security will be governed by the account rules of the
investors financial institution and of the depositary, as
well as general laws relating to securities transfers. We do not
recognize an indirect holder as a holder of securities and
instead deal only with the depositary that holds the global
security.
If securities are issued only in the form of a global security,
an investor should be aware of the following:
|
|
|
|
|
An investor cannot cause the securities to be registered in his
or her name, and cannot obtain non-global certificates for his
or her interest in the securities, except in the special
situations we describe below; |
|
|
|
An investor will be an indirect holder and must look to his or
her own bank or broker for payments on the securities and
protection of his or her legal rights relating to the
securities, as we describe above; |
|
|
|
An investor may not be able to sell interests in the securities
to some insurance companies and to other institutions that are
required by law to own their securities in non-book-entry form; |
|
|
|
An investor may not be able to pledge his or her interest in a
global security in circumstances where certificates representing
the securities must be delivered to the lender or other
beneficiary of the pledge in order for the pledge to be
effective; |
19
|
|
|
|
|
The depositarys policies, which may change from time to
time, will govern payments, transfers, exchanges and other
matters relating to an investors interest in a global
security. We and any applicable trustee have no responsibility
for any aspect of the depositarys actions or for its
records of ownership interests in a global security. We and the
trustee also do not supervise the depositary in any way; |
|
|
|
The depositary may, and we understand that DTC will, require
that those who purchase and sell interests in a global security
within its book-entry system use immediately available funds,
and your broker or bank may require you to do so as
well; and |
|
|
|
Financial institutions that participate in the depositarys
book-entry system, and through which an investor holds its
interest in a global security, may also have their own policies
affecting payments, notices and other matters relating to the
securities. There may be more than one financial intermediary in
the chain of ownership for an investor. We do not monitor and
are not responsible for the actions of any of those
intermediaries. |
Special Situations When a Global Security Will Be
Terminated
In a few special situations described below, the global security
will terminate and interests in it will be exchanged for
physical certificates representing those interests. After that
exchange, the choice of whether to hold securities directly or
in street name will be up to the investor. Investors must
consult their own banks or brokers to find out how to have their
interests in securities transferred to their own name, so that
they will be direct holders. We have described the rights of
holders and street name investors above.
The global security will terminate when the following special
situations occur:
|
|
|
|
|
if the depositary notifies us that it is unwilling, unable or no
longer qualified to continue as depositary for that global
security and we do not appoint another institution to act as
depositary within 90 days; |
|
|
|
if we notify any applicable trustee that we wish to terminate
that global security; or |
|
|
|
if an event of default has occurred with regard to securities
represented by that global security and has not been cured or
waived. |
The prospectus supplement may also list additional situations
for terminating a global security that would apply only to the
particular series of securities covered by the prospectus
supplement. When a global security terminates, the depositary,
and not we or any applicable trustee, is responsible for
deciding the names of the institutions that will be the initial
direct holders.
PLAN OF DISTRIBUTION
We may sell the securities through underwriters or dealers,
through agents, or directly to one or more purchasers. One or
more prospectus supplements will describe the terms of the
offering of the securities, including:
|
|
|
|
|
the name or names of any underwriters, if any; |
|
|
|
the purchase price of the securities and the proceeds we will
receive from the sale; |
|
|
|
any over-allotment options under which underwriters may purchase
additional securities from us; |
|
|
|
any agency fees or underwriting discounts and other items
constituting agents or underwriters compensation; |
|
|
|
any public offering price; |
|
|
|
any discounts or concessions allowed or reallowed or paid to
dealers; and |
|
|
|
any securities exchange or market on which the securities may be
listed. |
20
Only underwriters named in the prospectus supplement are
underwriters of the securities offered by the prospectus
supplement.
If underwriters are used in the sale, they will acquire the
securities for their own account and may resell the securities
from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of
sale. The obligations of the underwriters to purchase the
securities will be subject to the conditions set forth in the
applicable underwriting agreement. We may offer the securities
to the public through underwriting syndicates represented by
managing underwriters or by underwriters without a syndicate.
Subject to certain conditions, the underwriters will be
obligated to purchase all of the securities offered by the
prospectus supplement. Any public offering price and any
discounts or concessions allowed or reallowed or paid to dealers
may change from time to time. We may use underwriters with whom
we have a material relationship. We will describe in the
prospectus supplement, naming the underwriter, the nature of any
such relationship.
We may sell securities directly or through agents we designate
from time to time. We will name any agent involved in the
offering and sale of securities and we will describe any
commissions we will pay the agent in the prospectus supplement.
Unless the prospectus supplement states otherwise, our agent
will act on a best-efforts basis for the period of its
appointment. However, no prospectus supplement will
fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and
described in this prospectus at the time of its effectiveness.
We may authorize agents or underwriters to solicit offers by
certain types of institutional investors to purchase securities
from us at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for
payment and delivery on a specified date in the future. We will
describe the conditions to these contracts and the commissions
we must pay for solicitation of these contracts in the
prospectus supplement.
We may provide agents and underwriters with indemnification
against certain civil liabilities, including liabilities under
the Securities Act, or contribution with respect to payments
that the agents or underwriters may make with respect to such
liabilities. Agents and underwriters may engage in transactions
with, or perform services for, us in the ordinary course of
business.
All securities we offer, other than common stock, will be new
issues of securities with no established trading market. Any
underwriters may make a market in these securities, but will not
be obligated to do so and may discontinue any market making at
any time without notice. We cannot guarantee the liquidity of
the trading markets for any securities.
Any underwriter may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids in
accordance with Regulation M under the Exchange Act.
Overallotment involves sales in excess of the offering size,
which create a short position. Stabilizing transactions permit
bids to purchase the underlying security so long as the
stabilizing bids do not exceed a specified maximum price. Short
covering transactions involve purchases of the securities in the
open market after the distribution is completed to cover short
positions. Penalty bids permit the underwriters to reclaim a
selling concession from a dealer when the securities originally
sold by the dealer are purchased in a covering transaction to
cover short positions. Those activities may cause the price of
the securities to be higher than it would otherwise be. If
commenced, the underwriters may discontinue any of the
activities at any time.
Any underwriters who are qualified market makers on the NASDAQ
Global Market may engage in passive market making transactions
in the securities on the NASDAQ Global Market in accordance with
Rule 103 of Regulation M under the Exchange Act,
during the business day prior to the pricing of the offering,
before the commencement of offers or sales of the securities.
Passive market makers must comply with applicable volume and
price limitations and must be identified as passive market
makers. In general, a passive market maker must display its bid
at a price not in excess of the highest independent bid for such
security; if all independent bids are lowered below the passive
market makers bid, however, the passive market
makers bid must then be lowered when certain purchase
limits are exceeded.
21
In compliance with guidelines of the National Association of
Securities Dealers, or NASD, the maximum consideration or
discount to be received by any NASD member or independent broker
dealer may not exceed 8% of the aggregate amount of the
securities offered pursuant to this prospectus and any
applicable prospectus supplement.
LEGAL MATTERS
The validity of the securities being offered hereby will be
passed upon by Cooley Godward
llp
, Palo Alto, California.
EXPERTS
Ernst & Young LLP, Palo Alto, California independent
registered public accounting firm, has audited our financial
statements for the fiscal year ended December 31, 2005
included in our Annual Report on
Form 10-K for the
year ended December 31, 2005, as set forth in their report,
which is incorporated by reference in this prospectus and
elsewhere in the registration statement. These financial
statements are incorporated by reference in reliance on
Ernst & Young LLPs report given their authority
as experts in accounting and auditing.
Ernst & Young LLP, Cambridge, England, independent
registered public accounting firm, has audited our financial
statements for the fiscal years ended December 31, 2004 and
2003 included in our Annual Report on
Form 10-K for the
year ended December 31, 2005, as set forth in their report,
which is incorporated by reference in this prospectus and
elsewhere in the registration statement. These financial
statements are incorporated by reference in reliance on
Ernst & Young LLPs report given on their
authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements
and other information with the SEC. You may read and copy any
document we file at the SECs Public Reference Room at 100
F Street, N.E., Washington, D.C. 20549. Please call the SEC
at 1-800-SEC-0330 for
more information about the operation of the public reference
room. The SEC maintains an Internet site that contains reports,
proxy and information statements, and other information
regarding issuers that file electronically with the SEC,
including Solexa. The SECs Internet site can be found at
http://www.sec.gov.
INCORPORATION BY REFERENCE
We incorporate by reference into this prospectus the documents
listed below and any future filings we make with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended, including any filings after
the date of this prospectus but before the end of any offering
made under this prospectus. The SEC file number for the
documents incorporated by reference in this prospectus is
000-22570. We
incorporate by reference the following information that has been
filed with the SEC:
|
|
|
|
|
our annual report on
Form 10-K for the
year ended December 31, 2005 filed with the SEC on
March 31, 2006; |
|
|
|
our quarterly report on
Form 10-Q for the
quarter ended March 31, 2006 filed with the SEC on
May 15, 2006; |
|
|
|
our current report on
Form 8-K filed on
January 23, 2006; |
|
|
|
our current report on
Form 8-K filed on
March 28, 2006; |
|
|
|
our current report filed on
From 8-K/ A filed
on March 30, 2006; |
22
|
|
|
|
|
our current report filed on
Form 8-K/ A filed
on May 9, 2006; |
|
|
|
the description of our common stock set forth in our
registration statement on Form 10, as amended, filed on
October 5, 1993. |
Any information in any of the foregoing documents will
automatically be deemed to be modified or superseded to the
extent that information in this prospectus or in a later filed
document that is incorporated or deemed to be incorporated
herein by reference modifies or replaces such information.
We also incorporate by reference any future filings (other than
current reports furnished under Item 2.02 or Item 7.01
of Form 8-K and
exhibits filed on such form that are related to such items) made
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)
of the Exchange Act, until we file a post-effective amendment
which indicates the termination of the offering of the
securities made by this prospectus. Information in such future
filings updates and supplements the information provided in this
prospectus. Any statements in any such future filings will
automatically be deemed to modify and supersede any information
in any document we previously filed with the SEC that is
incorporated or deemed to be incorporated herein by reference to
the extent that statements in the later filed document modify or
replace such earlier statements.
We will provide to each person, including any beneficial owner,
to whom a prospectus is delivered, without charge upon written
or oral request, a copy of any or all of the documents that are
incorporated by reference into this prospectus but not delivered
with the prospectus, including exhibits which are specifically
incorporated by reference into such documents. Requests should
be directed to: Investor Relations, Solexa, Inc., 25861
Industrial Boulevard, Hayward, CA 94545, telephone:
(510) 670-9300.
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
FOR SECURITIES ACT LIABILITY
Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that
in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in
the Securities Act and will be governed by the final
adjudication of such issue.
23
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
|
|
Item 14. |
Other Expenses of Issuance and Distribution. |
The following table sets forth the estimated costs and expenses,
other than underwriting discounts and commissions, payable by
the registrant in connection with the offering of the securities
being registered. All the amounts shown are estimates, except
for the SEC registration fee.
|
|
|
|
|
SEC Registration Fee
|
|
$ |
10,700 |
|
Accounting Fees and Expenses
|
|
|
25,000 |
|
Legal Fees and Expenses
|
|
|
75,000 |
|
Trustee Fees and Expenses
|
|
|
20,000 |
|
Printing and Miscellaneous Expenses
|
|
|
15,000 |
|
|
|
|
|
Total
|
|
$ |
145,700 |
|
|
|
|
|
|
|
Item 15. |
Indemnification of Directors and Officers. |
As permitted by Delaware law, our amended and restated
certificate of incorporation provides that no director of ours
will be personally liable to us or our stockholders for monetary
damages for breach of fiduciary duty as a director, except for
liability:
|
|
|
|
|
for any breach of duty of loyalty to us or to our stockholders; |
|
|
|
for acts or omissions not in good faith or that involve
intentional misconduct or a knowing violation of law; |
|
|
|
for unlawful payment of dividends or unlawful stock repurchases
or redemptions under Section 174 of the Delaware General
Corporation Law; or |
|
|
|
for any transaction from which the director derived an improper
personal benefit. |
Our bylaws, as amended, further provides that we must indemnify
our directors and executive officers and may indemnify our other
officers and employees and agents to the fullest extent
permitted by Delaware law. We believe that indemnification under
our bylaws, as amended, covers negligence and gross negligence
on the part of indemnified parties.
We have entered into indemnification agreements with each of our
directors and certain officers. These agreements, among other
things, require us to indemnify each director and officer for
certain expenses including attorneys fees, judgments,
fines and settlement amounts incurred by any such person in any
action or proceeding, including any action by or in the right of
Solexa, Inc., arising out of the persons services as our
director or officer, any subsidiary of ours or any other company
or enterprise to which the person provides services at our
request. We have also obtained directors and officers insurance
to insure such persons against certain liabilities.
At present, there is no pending litigation or proceeding
involving a director or officer of Solexa as to which
indemnification is being sought nor are we aware of any
threatened litigation that may result in claims for
indemnification by any officer or director.
The underwriting agreement that we might enter into,
Exhibit 1.1 to this Registration Statement will provide for
indemnification by any underwriters of the registrant, its
directors, its officers who sign the registration statement and
its controlling persons for some liabilities, including
liabilities arising under the Securities Act of 1933, as amended.
The indemnification provisions noted above may be sufficiently
broad to permit indemnification of the registrants
officers and directors for liabilities arising under the
Securities Act of 1933, as amended.
II-1
(a) Exhibits
|
|
|
|
|
Exhibit |
|
|
Number |
|
Description of the Document |
|
|
|
|
1 |
.1 |
|
Form of Underwriting Agreement(1) |
|
3 |
.1 |
|
Amended and Restated Certificate of Incorporation of the
Company, incorporated by reference to the indicated exhibit of
the Companys Form 10-Q for the period ended
June 30, 2000 |
|
3 |
.1.1 |
|
Certificate of Amendment to Amended and Restated Certificate of
Incorporation of the Company, incorporated by reference to the
indicated exhibit of the Companys Form 10-K for the
period ended December 31, 2002 |
|
3 |
.1.2 |
|
Certificate of Amendment to Amended and Restated Certificate of
Incorporation of the Company, incorporated by reference to the
indicated exhibit of the Companys Current Report on
Form 8-K filed on March 7, 2005 |
|
3 |
.2 |
|
Bylaws of the Company, as amended, incorporated by reference to
the indicated exhibit of the Companys Form 10-Q for
the period ended June 30, 2000 |
|
3 |
.3 |
|
Certificate of Ownership and Merger of Lynx Therapeutics, Inc.,
incorporated by reference to the indicated exhibit of the
Companys Current Report on Form 8-K filed on
March 7, 2005 |
|
4 |
.1 |
|
Specimen Certificate of Common Stock, incorporated by reference
to the indicated exhibit of the Companys Form 10-Q
for the period ended March 31, 2005 |
|
4 |
.3 |
|
Form of Specimen Preferred Stock Certificate and Certificate of
Designation of Preferred Stock(1) |
|
4 |
.4 |
|
Form of Senior Debt Indenture, between Registrant and one or
more trustees to be named |
|
4 |
.5 |
|
Form of Subordinated Debt Indenture, between Registrant and one
or more trustees to be named |
|
4 |
.6 |
|
Form of Senior Note(1) |
|
4 |
.7 |
|
Form of Subordinated Note(1) |
|
4 |
.8 |
|
Form of Common Stock Warrant Agreement and Warrant Certificate |
|
4 |
.9 |
|
Form of Preferred Stock Warrant Agreement and Warrant Certificate |
|
4 |
.10 |
|
Form of Debt Securities Warrant Agreement and Warrant Certificate |
|
4 |
.11 |
|
Form of Unit Agreement(1) |
|
5 |
.1 |
|
Opinion of Cooley Godward
llp
|
|
12 |
.1 |
|
Statement Regarding Computation of Ratio of Earnings to Fixed
Charges |
|
23 |
.1 |
|
Consent of Independent Registered Public Accounting Firm |
|
23 |
.2 |
|
Consent of Independent Registered Public Accounting Firm |
|
23 |
.3 |
|
Consent of Cooley Godward
llp
(included in Exhibit 5.1) |
|
24 |
.1 |
|
Power of Attorney (included on signature page) |
|
|
(1) |
To be filed by amendment or as an exhibit to a current report of
the Registrant on
Form 8-K and
incorporated herein by reference, if applicable. |
Item 17. Undertakings.
The undersigned registrant hereby undertakes:
|
|
|
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration
statement: |
|
|
|
(i) To include any prospectus required by
Section 10(a)(3) of the Securities Act of 1933; |
|
|
(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in
volume of securities offered |
II-2
|
|
|
(if the total dollar value of securities offered would not
exceed that which was registered) and any deviation from the low
or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than 20 percent
change in the maximum aggregate offering price set forth in the
Calculation of Registration Fee table in the
effective registration statement; |
|
|
(iii) To include any material information with respect to
the plan of distribution not previously disclosed in the
registration statement or any material change to such
information in the registration statement; |
|
|
|
(A) the undertakings set forth in paragraphs (1)(i)
and (1)(ii) above do not apply if the registration statement is
on Form S-8, and the information required to be included in
a post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the Commission by the
registrant pursuant to section 13 or section 15(d) of
the Securities Exchange Act of 1934 that are incorporated by
reference in the registration statement; and |
|
|
(B) the undertakings set forth in paragraphs (1)(i),
(1)(ii) and (1)(iii) above do not apply if the registration
statement is on
Form S-3 or
form F-3 and the information required to be included in a
post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the Commission by the
registrant pursuant to Section 13 or Section 15(d) of
the Securities Exchange Act of 1934 that are incorporated by
reference in the registration statements or is contained in a
form of prospectus filed pursuant to Rule 424(b) that is a
part of the registration statement. |
|
|
(C) Provided further, however, that
paragraphs (1)(i) and (1)(ii) above do not apply if the
registration statement is for an offering of asset-backed
securities on
Form S-1 or
Form S-3, and the
information required to be included in a post-effective
amendment is provided pursuant to Item 1100(c) of
Regulation AB. |
|
|
|
(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof. |
|
|
(3) To remove from registration by means of a
post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering. |
|
|
(4) That, for the purpose of determining liability of the
registrant under the Securities Act of 1933 to any purchaser in
the initial distribution of the securities, the undersigned
registrant undertakes that in a primary offering of securities
of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell
the securities to the purchaser, if the securities are offered
or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such
securities to such purchaser: (i) Any preliminary
prospectus or prospectus of the undersigned registrant relating
to the offering required to be filed pursuant to Rule 424;
(ii) any free writing prospectus relating to the offering
prepared by or on behalf of the undersigned registrant or used
or referred to by the undersigned registrant; (iii) the
portion of any other free writing prospectus relating to the
offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the
undersigned registrant; and (iv) any other communication
that is an offer in the offering made by the undersigned
registrant to the purchaser. |
|
|
(5) That: (i) for purposes of determining any
liability under the Securities Act of 1933, the information
omitted from the form of prospectus filed as part of the
registration statement in reliance upon Rule 430A and
contained in the form of prospectus filed by the registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the
Securities Act shall be deemed to be part of the registration |
II-3
|
|
|
statement as of the time it was declared effective; and
(ii) for the purpose of determining any liability under the
Securities Act, each post-effective amendment that contains a
form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof. |
|
|
(6) That, for purposes of determining any liability under
the Securities Act of 1933, each filing of the registrants
annual report pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each
filing of an employee benefit plans annual report pursuant
to Section 15(d) of the Securities Exchange Act of 1934)
that is incorporated by reference in the registration statement
shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial
bona fide offering thereof. |
|
|
(7) To file an application for the purpose of determining
the eligibility of the trustee to act under
subsection (a) of Section 310 of the
Trust Indenture Act (the Act) in accordance
with the rules and regulations prescribed by the Commission
under Section 305(b)(2) of the Act. |
That, for the purpose of determining liability under the
Securities Act of 1933 to any purchaser:
(i) Each prospectus filed by the registrant pursuant to
Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and
(ii) Each prospectus required to be filed pursuant to
Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering
made pursuant to Rule 415(a)(1)(i), (vii), or (x) for
the purpose of providing the information required by section
10(a) of the Securities Act of 1933 shall be deemed to be part
of and included in the registration statement as of the earlier
of the date such form of prospectus is first used after
effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As
provided in Rule 430B, for liability purposes of the issuer
and any person that is at that date an underwriter, such date
shall be deemed to be a new effective date of the registration
statement relating to the securities in the registration
statement to which that prospectus relates, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof. Provided, however, that no statement
made in a registration statement or prospectus that is part of
the registration statement or made in a document incorporated or
deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made
in the registration statement or prospectus that was part of the
registration statement or made in any such document immediately
prior to such effective date.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers
and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Act and will be
governed by the final adjudication of such issue.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on
Form S-3 and has
duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the
City of Hayward, State of California, on May 18, 2006.
|
|
|
|
|
John West |
|
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints John West and
Linda Rubinstein, and each of them, as true and lawful
attorneys-in-fact and
agents, with full powers of substitution and resubstitution, for
them and in their name, place and stead, in any and all
capacities, to sign any and all amendments (including
pre-effective and post-effective amendments) to this
registration statement and any additional registration
statements filed pursuant to Rule 462, and to file the
same, with all exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange
Commission (the SEC), and generally to do all such
things in their names and behalf in their capacities as officers
and directors to enable the registrant to comply with the
provisions of the Securities Act and all requirements of the
SEC, granting unto said
attorneys-in-fact and
agents, and each of them, full power and authority to do and
perform each and every act and thing requisite and necessary to
be done in connection therewith, as fully to all intents and
purposes as he or she might or could do in person, ratifying and
confirming all that said
attorneys-in-fact and
agents, or any of them, or their or his substitutes or
substitute, may lawfully do or cause to be done by virtue hereof.
|
|
|
|
|
|
|
Signatures |
|
Title |
|
Date |
|
|
|
|
|
|
/s/ John West
John
West |
|
Chief Executive Officer and Director
(Principal Executive Officer) |
|
May 18, 2006 |
|
/s/ Linda Rubinstein
Linda
Rubinstein |
|
Vice President and
Chief Financial Officer
(Principal Accounting and
Financial Officer) |
|
May 18, 2006 |
|
/s/ Craig C. Taylor
Craig
C. Taylor |
|
Chairman of the Board |
|
May 18, 2006 |
|
/s/ Stephen Allen
Stephen
Allen |
|
Director |
|
May 18, 2006 |
|
/s/ Douglas Fambrough
Douglas
Fambrough |
|
Director |
|
May 18, 2006 |
II-5
|
|
|
|
|
|
|
Signatures |
|
Title |
|
Date |
|
|
|
|
|
|
/s/ Hermann Hauser
Hermann
Hauser |
|
Director |
|
May 18, 2006 |
|
/s/ Genghis Lloyd-Harris
Genghis
Lloyd-Harris |
|
Director |
|
May 18, 2006 |
|
/s/ G. Mason Morfit
G.
Mason Morfit |
|
Director |
|
May 18, 2006 |
II-6
EXHIBITS INDEX
|
|
|
|
|
Exhibit |
|
|
Number |
|
Description of the Document |
|
|
|
|
1 |
.1 |
|
Form of Underwriting Agreement(1) |
|
3 |
.1 |
|
Amended and Restated Certificate of Incorporation of the
Company, incorporated by reference to the indicated exhibit of
the Companys Form 10-Q for the period ended
June 30, 2000 |
|
3 |
.1.1 |
|
Certificate of Amendment to Amended and Restated Certificate of
Incorporation of the Company, incorporated by reference to the
indicated exhibit of the Companys Form 10-K for the
period ended December 31, 2002 |
|
3 |
.1.2 |
|
Certificate of Amendment to Amended and Restated Certificate of
Incorporation of the Company, incorporated by reference to the
indicated exhibit of the Companys Current Report on
Form 8-K filed on March 7, 2005 |
|
3 |
.2 |
|
Bylaws of the Company, as amended, incorporated by reference to
the indicated exhibit of the Companys Form 10-Q for
the period ended June 30, 2000 |
|
3 |
.3 |
|
Certificate of Ownership and Merger of Lynx Therapeutics, Inc.,
incorporated by reference to the indicated exhibit of the
Companys Current Report on Form 8-K filed on
March 7, 2005 |
|
4 |
.1 |
|
Specimen Certificate of Common Stock, incorporated by reference
to the indicated exhibit of the Companys Form 10-Q
for the period ended March 31, 2005 |
|
4 |
.3 |
|
Form of Specimen Preferred Stock Certificate and Certificate of
Designation of Preferred Stock(1) |
|
4 |
.4 |
|
Form of Senior Debt Indenture, between Registrant and one or
more trustees to be named |
|
4 |
.5 |
|
Form of Subordinated Debt Indenture, between Registrant and one
or more trustees to be named |
|
4 |
.6 |
|
Form of Senior Note(1) |
|
4 |
.7 |
|
Form of Subordinated Note(1) |
|
4 |
.8 |
|
Form of Common Stock Warrant Agreement and Warrant Certificate |
|
4 |
.9 |
|
Form of Preferred Stock Warrant Agreement and Warrant Certificate |
|
4 |
.10 |
|
Form of Debt Securities Warrant Agreement and Warrant Certificate |
|
4 |
.11 |
|
Form of Unit Agreement(1) |
|
5 |
.1 |
|
Opinion of Cooley Godward
llp
|
|
12 |
.1 |
|
Statement Regarding Computation of Ratio of Earnings to Fixed
Charges |
|
23 |
.1 |
|
Consent of Independent Registered Public Accounting Firm |
|
23 |
.2 |
|
Consent of Independent Registered Public Accounting Firm |
|
23 |
.3 |
|
Consent of Cooley Godward
llp
(included in Exhibit 5.1) |
|
24 |
.1 |
|
Power of Attorney (included on signature page) |
|
|
(1) |
To be filed by amendment or as an exhibit to a current report of
the Registrant on
Form 8-K and
incorporated herein by reference, if applicable. |